Drug Discovery World

MAY 16, 2023

Investment landscape In 2023, Matthieu de Kalbermatten, CEO of CellProthera, looks forward to presenting the final safety and efficacy results of the company’s Phase II clinical trial, and for moving into Phase III. Lending to the time-to-clinic discrepancy, we also see increasing demands on manufacturing capacity for CGT reagents.”

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. GSK has developed high-throughput mammalian and E. To demonstrate the utility of the company’s SYNTAX system in gene assembly, the 1.7

Antibody 59

Antibody Protein Engineer In-Vivo 59

XTalks

OCTOBER 1, 2020

Dr. Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. They felt there could be no one better than Dr. Lin to do business development and look for compounds that fit their drug delivery technology.

Scientist 52

Scientist In-Vitro Research Life Science 52